Anna Szczepańska-Buda

Anna Szczepańska-Buda has a diverse work experience in the field of project management and clinical trials. Anna is currently working at WPD Pharmaceuticals Inc. as a Project Manager, a role they have held since February 2023. Prior to this, they worked as a Junior Project Manager at the same company from October 2022 to January 2023. Anna also served as an R&D Specialist from November 2021 to September 2022.

Before joining WPD Pharmaceuticals Inc., Anna worked at Centrum Badawczo-Rozwojowe Novasome Sp. z o.o. (Grupa Hasco) for several years. Their roles there included Clinical Trials Centre Manager from June 2021 to October 2021, Clinical Trials Coordinator from May 2018 to May 2021, Specialist in medical technology/Clinical Trials Coordinator from May 2018 to November 2019, and Junior Specialist in medical technology from March 2016 to May 2018. Their responsibilities involved various aspects of clinical trial management, such as developing documentation, coordinating study procedures, and ensuring adherence to protocols and regulations.

Anna's early work experience includes a role as a Junior Assistant in the laboratory at Wrovasc – Integrated Cardiovascular Centre from June 2012 to May 2018.

Overall, Anna Szczepańska-Buda has gained valuable experience in project management and clinical trial coordination throughout their career.

Anna Szczepańska-Buda completed their postgraduate studies in Management for Engineers at Wroclaw University of Economics and Business from 2017 to 2018. Prior to that, they obtained their M.Sc. degree in Biotechnology - Molecular Biotechnology and Biocatalysis from Wroclaw University of Science and Technology, where they studied from 2007 to 2012. Additionally, they have obtained several certifications, including "Certyfikat ukończenia szkolenia IQVIA CRA School" from IQVIA in February 2019, "Transporting Dangerous Goods Training - IATA Certificate" from Mayo Clinic in September 2020, and "Good Clinical Practice" from NIDA Clinical Trials Network in July 2018.